Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
![[68Ga]FAPI-46 in Pneumoconiosis: NCT05365802 Clinical Landscape Report 2026](https://synapse-static.patsnap.com/strapi-static/Blog_cover_02_0815c5db75.jpg)
9 min read
[68Ga]FAPI-46 in Pneumoconiosis: NCT05365802 Clinical Landscape Report 2026
16 October 2026
NCT05365802 clinical landscape for Pneumoconiosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Saroglitazar in Metabolic Dysfunction Associated Steatohepatitis: CTRI/2022/05/042462 Clinical Landscape Report 2026
16 October 2026
CTRI/2022/05/042462 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context an…
9 min read
Ibutamoren Mesylate in Metabolic Dysfunction Associated Steatohepatitis: NCT05364684 Clinical Landscape Report 2026
16 October 2026
NCT05364684 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Nonacog beta pegol in Hemorrhage: NCT05365217 Clinical Landscape Report 2026
16 October 2026
NCT05365217 clinical landscape for Hemorrhage: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
L-Glutamine in Vaso-occlusive crisis: NCT05371184 Clinical Landscape Report 2026
16 October 2026
NCT05371184 clinical landscape for Vaso-occlusive crisis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Yinfenidone Hydrochloride in Idiopathic Pulmonary Fibrosis: NCT05383131 Clinical Landscape Report 2026
16 October 2026
NCT05383131 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cudetaxestat in Idiopathic Pulmonary Fibrosis: NCT05373914 Clinical Landscape Report 2026
16 October 2026
NCT05373914 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Deferasirox in stress oxidative: NCT05392101 Clinical Landscape Report 2026
16 October 2026
NCT05392101 clinical landscape for stress oxidative: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Brigimadlin in Glioblastoma: NCT05376800 Clinical Landscape Report 2026
16 October 2026
NCT05376800 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sirolimus in Acute Chest Syndrome: NCT05384756 Clinical Landscape Report 2026
16 October 2026
NCT05384756 clinical landscape for Acute Chest Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Bersiporocin hydrochloride in Idiopathic Pulmonary Fibrosis: NCT05389215 Clinical Landscape Report 2026
16 October 2026
NCT05389215 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ansornitinib in Idiopathic Pulmonary Fibrosis: NCT05387785 Clinical Landscape Report 2026
16 October 2026
NCT05387785 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.